NASDAQ:TOCA - Tocagen Stock Price, Forecast & News

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.10. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative net margin of 201,488.91% and a negative return on equity of 182.15%. View Tocagen's Earnings History.

Tocagen is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Tocagen.

9 equities research analysts have issued 12 month price objectives for Tocagen's stock. Their forecasts range from $1.00 to $28.00. On average, they expect Tocagen's share price to reach $8.22 in the next year. This suggests a possible upside of 410.6% from the stock's current price. View Analyst Price Targets for Tocagen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.

News coverage about TOCA stock has trended somewhat negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tocagen earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Tocagen.

Tocagen saw a decrease in short interest in January. As of January 15th, there was short interest totalling 2,020,000 shares, a decrease of 14.4% from the December 31st total of 2,360,000 shares. Based on an average daily trading volume, of 533,200 shares, the short-interest ratio is presently 3.8 days. Currently, 9.2% of the company's stock are short sold. View Tocagen's Current Options Chain.

Some companies that are related to Tocagen include Fortress Biotech (FBIO), Akorn (AKRX), ContraFect (CFRX), Cerecor (CERC), Five Prime Therapeutics (FPRX), Evelo Biosciences (EVLO), Kezar Life Sciences (KZR), Scpharmaceuticals (SCPH), GlycoMimetics (GLYC), Tyme Technologies (TYME), Selecta Biosciences (SELB), Marinus Pharmaceuticals (MRNS), Avenue Therapeutics (ATXI), Verastem (VSTM) and Ovid Therapeutics (OVID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Catalyst Pharmaceuticals (CPRX), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and Aduro BioTech (ADRO).

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Tocagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.24%), Geode Capital Management LLC (1.38%), Acadian Asset Management LLC (0.90%) and Goldman Sachs Group Inc. (0.20%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Institutional Ownership Trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Tocagen.

TOCA stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Insider Buying and Selling for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $1.61.

Tocagen has a market capitalization of $38.48 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.

The official website for Tocagen is http://www.tocagen.com/.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]